Figure 2. miR-136-5p directly binds to IL-6 and CRP and downregulates their expression. (A) The binding sites between miR-136-5p and IL-6 as well as between miR-136-5p and CRP predicted by using a web-based bioinformatic prediction resource. (B) The interaction between miR-136-5p and IL-6 verified by dual-luciferase reporter gene assay. (C) The interaction between miR-136-5p and CRP verified by dual-luciferase reporter gene assay. (D) The level of IL-6 in the culture medium supernatant of HUVECs after alteration of miR-136-5p expression, as detected by ELISA. (E) The level of CRP in the culture medium supernatant of HUVECs after alteration of miR-136-5p, as detected by ELISA. * p < 0.05 vs. treatment of NC agomir; # p < 0.05 vs. treatment of NC antagomir. Measurement data were expressed as mean ± standard deviation. Data from two groups were compared using independent sample t-test. Each experiment was repeated three times. miR-136-5p, microRNA-136-5p; IL-6, interleukin-6; CRP, C-reactive protein; ELISA, enzyme linked immunosorbent assay; HUVECs, human umbilical vein endothelial cells; ANOVA, analysis of variance.